Theodoros Karantanos, M.D., Ph.D.

Headshot of Theodoros Karantanos
  • Assistant Professor of Oncology

Languages: English, Greek

Expertise

Acute Leukemia, Myelodysplastic Syndromes (MDS), Myelodysplastic/Myeloproliferative Neoplasms ...read more

Research Interests

Molecular biology of MDS and AML

Background

Dr. Karantanos graduated from the School of Health Sciences at the University of Athens, Greece and received a Ph.D. in cancer biology. As a post-doctoral research fellow at MD Anderson Cancer Center/University of Texas, he studied signal transduction in cancer and developed expertise in mouse modeling and targeted therapies. He completed his internal medicine residency and Chief residency training at Boston University and his medical oncology fellowship training at Johns Hopkins. His clinical research focused on sex-related differences in the genomic profile and outcomes of MPN and MDS/MPN patients. As a research fellow he studied malignant hematopoiesis and his work led to the identification of CCRL2, as an inducer of MDS/sAML cells growth and a mediator of azacitidine resistance.

...read more

Titles

  • Assistant Professor of Oncology

Departments / Divisions

Education

Degrees

  • MD; Athens School of Health Sciences (2011)

Residencies

  • Internal Medicine; Boston Medical Center (2017)

Fellowships

  • Oncology; Johns Hopkins University School of Medicine (2022)

Board Certifications

  • American Board of Internal Medicine (Internal Medicine) (2017)
  • American Board of Internal Medicine (Medical Oncology) (2020)

Research & Publications

Research Summary

My research focuses on the dissection of growth signaling regulation in MDS and MDS/MPN and mechanisms implicated in the progression of chronic myeloid diseases to AML. My work incorporates gene editing by CRISPR-Cas9, signal transduction analysis, progenitor assays, drug screens and MDS/AML xenograft models.

Our lab studies the molecular biology of growth signaling regulation in MDS and MDS/MPN and investigates novel therapies that can effectively target these pathways using in vitro and in vivo models.

Selected Publications

View all on PubMed

Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R, Helmenstine E, Rajkhowa T, Paun BC, Bonifant C, Dalton WB, Gondek LP, Moliterno AR, Levis MJ, Ghiaur G, Jones RJ. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. Sci Adv. 2022 Feb 18;8(7):eabl8952

Karantanos T, Teodorescu P, Arvanitis M, Perkins B, Jain T, DeZern AE, Dalton WB, Christodoulou I, Paun BC, Varadhan R, Esteb C, Rajkhowa T, Bonifant C, Gondek LP, Levis MJ, Yegnasubramanian S, Ghiaur G, Jones RJ. CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine. Haematologica. 2022 Dec 15

Karantanos T, Gondek LP, Varadhan R. Moliterno AR, Dezern AE, Jones RJ, Jain T. Gender-related differences in the outcomes and genomic landscape of patients with MDS/MPN. Br J Haematol. 2021 Jun;193(6):1142-1150

Karantanos T, Chaturvedi S, Braunstein EM, Spivak JL, Resar L, Karanika S, Williams D, Rogers O, Gocke C, Moliterno AR. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020 Jun 23;4(12):2567-2576

Karantanos T, Tsai HL, Gondek LP, DeZern AE, Ghiaur G, Dalton WB, Gojo I, Prince GT, Webster J, Ambinder A, Smith BD, Levis MJ, Varadhan R, Jones RJ, Jain T. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leuk Lymphoma. 2022 Aug;63(8):1942-1948

Activities & Honors

Honors

  • K08 Clinical Scientist Research Career Development Award, NIH/NHLBI, 2023 - 2028
  • Passano Award, Passano Foundation, 2023
  • Clinician Scientist Award, Johns Hopkins University, 2023
  • MacMillan Pathway to Independence Program, Sidney Kimmel Cancer Center, 2022
  • Research Training Award for Fellows, American Society of Hematology, 2021 - 2023
  • Physician Scientist Johns Hopkins Training Program Grant, 2021
  • T32 Training Program in Hematology, Johns Hopkins University, 2019 - 2021
  • Prostate Cancer Foundation (PCF) Young Investigator Award, 2013
  • Hellenic Society of Medical Oncology Young Investigator Award, 2012

Memberships

  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • American Society of Transplantation and Cellular Therapy

Professional Activities

  • Leukemia Service Attending

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Is this you? Edit Profile
back to top button